PT2857037T - Agente para prevenção e/ou tratamento de dor neuropática periférica causada por fármaco anticanceroso - Google Patents

Agente para prevenção e/ou tratamento de dor neuropática periférica causada por fármaco anticanceroso

Info

Publication number
PT2857037T
PT2857037T PT13796572T PT13796572T PT2857037T PT 2857037 T PT2857037 T PT 2857037T PT 13796572 T PT13796572 T PT 13796572T PT 13796572 T PT13796572 T PT 13796572T PT 2857037 T PT2857037 T PT 2857037T
Authority
PT
Portugal
Prior art keywords
preventing
agent
neuropathic pain
cancer drug
pain caused
Prior art date
Application number
PT13796572T
Other languages
English (en)
Inventor
Atsufumi Kawabata
Hideaki Suzuki
Original Assignee
Univ Kinki
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kinki, Asahi Kasei Pharma Corp filed Critical Univ Kinki
Publication of PT2857037T publication Critical patent/PT2857037T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT13796572T 2012-05-31 2013-05-17 Agente para prevenção e/ou tratamento de dor neuropática periférica causada por fármaco anticanceroso PT2857037T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012125316 2012-05-31

Publications (1)

Publication Number Publication Date
PT2857037T true PT2857037T (pt) 2019-07-19

Family

ID=49673113

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13796572T PT2857037T (pt) 2012-05-31 2013-05-17 Agente para prevenção e/ou tratamento de dor neuropática periférica causada por fármaco anticanceroso

Country Status (21)

Country Link
US (1) US10709767B2 (pt)
EP (1) EP2857037B1 (pt)
JP (3) JP6124417B2 (pt)
KR (1) KR101672114B1 (pt)
CN (1) CN104394885B (pt)
AU (1) AU2013268725B2 (pt)
BR (1) BR112014028852A2 (pt)
CA (1) CA2875069C (pt)
DK (1) DK2857037T3 (pt)
ES (1) ES2743767T3 (pt)
HK (1) HK1203846A1 (pt)
HU (1) HUE045997T2 (pt)
IL (1) IL235984B (pt)
IN (1) IN2014DN10075A (pt)
MX (1) MX364934B (pt)
NZ (1) NZ702242A (pt)
PL (1) PL2857037T3 (pt)
PT (1) PT2857037T (pt)
RU (1) RU2595857C2 (pt)
WO (1) WO2013179910A1 (pt)
ZA (1) ZA201408769B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013179910A1 (ja) * 2012-05-31 2013-12-05 学校法人近畿大学 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP6325036B2 (ja) * 2016-08-19 2018-05-16 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
CN110446494A (zh) * 2017-03-31 2019-11-12 东丽株式会社 周围神经病变的治疗剂或预防剂
WO2019123144A1 (en) * 2017-12-19 2019-06-27 Synergia Life Sciences Pvt. Ltd. Vitamin k2 compositions for the treatment of drug induced neuropathy
US11497795B2 (en) * 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
AU2019347406B9 (en) * 2018-09-28 2023-11-16 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
EP0816494A1 (en) 1987-01-08 1998-01-07 Asahi Kasei Kogyo Kabushiki Kaisha DNA coding for a peptide promoting the activation of protein C by thrombin, and process for producing the same
EP0285511B1 (en) 1987-04-01 1992-11-25 Mitsubishi Gas Chemical Company, Inc. Immunoassay of thrombomodulin
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
WO1992000325A1 (en) 1990-06-27 1992-01-09 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
AU6235994A (en) 1993-02-25 1994-09-14 Abbott Laboratories Multipurpose reagent system for rapid lysis of whole blood samples
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
DE69534016T2 (de) 1994-04-20 2006-03-23 Asahi Kasei Pharma Corp. Verwendung von thrombomodulin gegen lebererkrankungen
JPH083065A (ja) 1994-04-20 1996-01-09 Asahi Chem Ind Co Ltd 肝臓障害に対する治療剤
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
ES2244968T3 (es) 1995-03-06 2005-12-16 Interneuron Pharmaceuticals Incorporated Reduccion del volumen de infarto usando citocolina.
JP3789147B2 (ja) 1995-04-11 2006-06-21 旭化成ファーマ株式会社 脊髄損傷後の神経障害に対する治療剤
JPH08301783A (ja) 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
JP3931353B2 (ja) 1995-06-30 2007-06-13 持田製薬株式会社 創傷治癒剤
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JPH101439A (ja) 1996-06-11 1998-01-06 Mochida Pharmaceut Co Ltd 神経変性疾患治療剤
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
ATE298246T1 (de) 2000-03-28 2005-07-15 Lilly Co Eli Aktiviertes protein c zur behandlung von pankreatitis
US20020111296A1 (en) 2000-08-31 2002-08-15 Festoff Barry W. Thrombomodulin analogs for use in recovery of spinal cord injury
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
EP1664041B1 (en) * 2003-09-22 2008-07-02 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
EP1848994A2 (en) * 2005-02-16 2007-10-31 Wyeth Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
CN101801187B (zh) 2007-07-13 2014-07-23 得克萨斯系统大学评议会 大麻素受体的杂环调节剂
BRPI0908217A2 (pt) * 2008-02-18 2015-08-25 Esteve Labor Dr Uso de compostos de ligação aos ligantes do receptor sigma para o tratamento de dor neuropática desenvolvida como uma consequência de quimioterapia
EP2320936A1 (en) * 2008-07-16 2011-05-18 PAION Deutschland GmbH Prevention and treatment of radiation injury
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
JP2011178687A (ja) 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5924611B2 (ja) 2010-06-16 2016-05-25 国立大学法人高知大学 造血細胞移植に伴う生着症候群の予防及び／又は治療のための医薬
US8747844B2 (en) * 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2013179910A1 (ja) 2012-05-31 2013-12-05 学校法人近畿大学 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Also Published As

Publication number Publication date
JP6427284B2 (ja) 2018-11-21
CA2875069C (en) 2018-01-02
EP2857037A4 (en) 2016-04-06
JP2017141268A (ja) 2017-08-17
KR101672114B1 (ko) 2016-11-02
AU2013268725B2 (en) 2017-02-16
EP2857037A1 (en) 2015-04-08
IL235984A0 (en) 2015-01-29
MX2014014505A (es) 2015-06-02
CN104394885B (zh) 2017-06-30
ZA201408769B (en) 2015-12-23
RU2014148171A (ru) 2016-07-20
WO2013179910A1 (ja) 2013-12-05
HK1203846A1 (en) 2015-11-06
IN2014DN10075A (pt) 2015-08-21
US20150148296A1 (en) 2015-05-28
IL235984B (en) 2019-09-26
CA2875069A1 (en) 2013-12-05
DK2857037T3 (da) 2019-07-22
PL2857037T3 (pl) 2019-12-31
HUE045997T2 (hu) 2020-01-28
MX364934B (es) 2019-03-28
JPWO2013179910A1 (ja) 2016-01-18
JP2018095652A (ja) 2018-06-21
EP2857037B1 (en) 2019-06-26
BR112014028852A2 (pt) 2018-04-24
KR20150004855A (ko) 2015-01-13
NZ702242A (en) 2016-03-31
CN104394885A (zh) 2015-03-04
AU2013268725A1 (en) 2014-12-18
RU2595857C2 (ru) 2016-08-27
JP6124417B2 (ja) 2017-05-10
JP6279788B2 (ja) 2018-02-14
US10709767B2 (en) 2020-07-14
ES2743767T3 (es) 2020-02-20

Similar Documents

Publication Publication Date Title
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
EP2740795A4 (en) MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2818481A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
PT2832366T (pt) Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
PL2908758T3 (pl) Lektromagnetyczne urządzenie do zabiegów na skórze
EP2819703A4 (en) TREATMENT OF PAIN
EP2897598A4 (en) TRANSDERMIC DRUG DELIVERY DEVICE
HK1203846A1 (en) Agent for preventing and or treating peripheral neuropathic pain caused by anti-cancer drug
EP3025716A4 (en) SUBSTANCE FOR TREATING OR TREATING PAIN
EP2911753A4 (en) THERAPY DEVICE FOR PINE CLAMP PREPARATION AND TREATMENT
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
EP2842568A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF TYPE I DIABETES AND THE USE THEREOF
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
IL246286B (en) A medical preparation for the prevention and treatment of advanced myopia.
EP2854786A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATION AND PAIN
ZA201408065B (en) Compositions and methods for the treatment of diabetes
EP2854785A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION AND PAIN
EP2866555A4 (en) DOSAGE REGIME FOR THE TREATMENT OF ANIMAL
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF
HK1212587A1 (zh) 用於預防或者治療糖尿病的製劑